Zyla Life Sciences Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-19: Form 8-K; Period of report 2019-12-17; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2019-11-14: Form 8-K; Period of report 2019-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-10-30: Form 8-K; Period of report 2019-10-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-10-23: Form 8-K; Period of report 2019-10-22; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-19 | 8-K | 2019-12-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On December 17, 2019, Zyla Life Sciences (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”). | tm1926688-1_8k.htm |
| 2019-11-14 | 8-K | 2019-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2019, Zyla Life Sciences (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2019. | a19-22773_18k.htm |
| 2019-10-30 | 8-K | 2019-10-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with Robert Radie’s resignation as President and Chief Executive Officer of the Company effective as of October 22, 2019, the Company and Mr. Radie agreed on the terms of Mr. Radie’s separation on October 30, 2019. | a19-21507_18k.htm |
| 2019-10-23 | 8-K | 2019-10-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective October 22, 2019, Robert S. Radie, the President and Chief Executive Officer and a director of Zyla Life Sciences (the “Company”) voluntarily resigned as President and Chief Executive Officer and as a director of the Company. | a19-20779_18k.htm |
| 2019-08-30 | 8-K | 2019-08-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 26, 2019, Zyla Life Sciences (the “Company”) granted an executive retention award to Mark Strobeck, PhD, the Company’s Executive Vice President and Chief Operating Officer, after approval by the Compensation Committee of the Board of Directors of the Company, to be paid in accordance with the terms of a Retention Bonus Agreement (the “Retention Agreement”) between Dr. Strobeck and the Company. | a19-18020_18k.htm |
| 2019-08-13 | 8-K | 2019-08-13 | 2.02 Results of Operations and Financial Condition | 2.02 On August 13, 2019, Zyla Life Sciences (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2019. | a19-16875_18k.htm |
| 2019-08-01 | 8-K | 2019-07-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a19-16354_18k.htm |
| 2019-06-20 | 8-K | 2019-06-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On June 18, 2019, the Board of Directors (the “Board”) of Zyla Life Sciences (the “Company”) appointed Gary M. Phillips, M.D. as a director of the Company. | a19-11802_18k.htm |
| 2019-06-06 | 8-K | 2019-05-31 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 On May 31, 2019, Zyla Life Sciences (formerly known as Egalet Corporation) (the “Company”) entered into Amendment No. 3 (the “Third Amendment”) to the Asset Purchase Agreement, dated as of October 30, 2018, by and among Iroko Pharmaceuticals, Inc. (“Iroko”), Zyla Life Sciences US Inc. (formerly Egalet US Inc.) (together with the Company, the “Buyer”), and the Company, as amended (the “Asset Purchase Agreement”). 5.02 On June 5, 2019, Luke Dűster notified the Company of his resignation from the Board of Directors of the Company (the “Board”). 5.03 Effective June 3, 2019, the Company changed its name to Zyla Life Sciences by filing an amendment to its Certificate of Incorporation. | a19-11195_18k.htm |
| 2019-05-16 | 8-K | 2019-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 16, 2019, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2019. | a19-10081_18k.htm |
| 2019-05-03 | 8-K | 2019-04-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The board of directors of Egalet Corporation (the “Company”) appointed Robert Radie, the Company’s President and Chief Executive Officer, as its principal financial officer effective April 29, 2019. | a19-9339_18k.htm |
| 2019-04-17 | 8-K | 2019-04-17 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for the purposes of Regulation FD is a presentation to be given by management of Egalet Corporation (the “Company”) to potential investors on April 17, 2019. | a19-8483_18k.htm |
| 2019-04-16 | 8-K/A | 2019-01-31 | 9.01 Financial Statements and Exhibits | 9.01 (a) Financial Statements of Businesses Acquired. | f8-ka.htm |
| 2019-04-01 | 8-K | 2019-03-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 26, 2019, the Board of Directors (the “Board”) of Egalet Corporation (the “Company”) approved an Amended and Restated Egalet Corporation 2019 Stock-Base Incentive Compensation Plan (the “Stock Plan”) for the benefit of employees, non-employee directors and consultants of the Company and its subsidiaries and affiliates. | a19-7552_18k.htm |
| 2019-03-20 | 8-K | 2019-03-20 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information required by this Item 2.03 relating to the Revolving Credit Agreement set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | a19-6876_18k.htm |
| 2019-02-01 | 8-K | 2019-01-31 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 5.03 On February 1, 2019, in accordance with the Plan, the Company’s Fourth Amended and Restated Certificate of Incorporation (as amended and restated, the “A&R Charter”) was filed with the Secretary of State of the State of Delaware, at which time the A&R Charter became effective. 7.01 The Company is currently engaged in discussions with potential lenders to provide financing to the Company in the form of a revolving credit facility, line of credit or similar debt facility of approximately $20 million in aggregate principal amount. | a19-3875_28k.htm |
| 2019-02-01 | 8-K | 2019-01-31 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 1.03 As previously announced and noted above, on January 14, 2019, the Court entered the Confirmation Order confirming the Plan under Chapter 11 of the Bankruptcy Code. 2.01 The information required by this Item 2.01 relating to the Iroko Acquisition set forth under the Explanatory Note or Item 1.01 of this Current Report on Form 8-K and is incorporated herein by reference. 2.03 The information required by this Item 2.03 relating to the Notes, the Indenture and the Interim Promissory Note set forth under the Explanatory Note or Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 On the Effective Date, all existing equity interests, including all existing shares of old common stock, of the Company were cancelled pursuant to the Plan. 3.03 The information required by this Item 3.03 and set forth under the Explanatory Note, Item 1.01, Item 1.02, Item 1.03 or Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.01 Upon the effectiveness of the Plan and the Iroko Acquisition, (i) Iroko, together with certain of its affiliates, owns approximately 49% of the outstanding common stock of the Company and (ii) the former holders of First Lien Secured Notes Claims and Convertible Notes Claims own, in the aggregate, approximately 51% of the outstanding common stock of the Company. 5.02 Pursuant to the Plan, a new board of directors of the Company took office as of the Effective Date, consisting of: Robert S. Radie; Andrea Heslin Smiley; Timothy P. Walbert (collectively with Mr. Radie and Ms. Smiley, the “Continuing Directors”); Joseph McInnis; Luke Düster; Todd Holmes; and Matthew Pauls. | a19-3875_18k.htm |
| 2019-01-16 | 8-K | 2019-01-14 | 1.03 Bankruptcy or Receivership | 1.03 As previously reported, on October 30, 2018, Egalet Corporation (the “Company” or “Egalet Corp.”) and its wholly-owned subsidiaries (collectively with the Company, the “Debtors”), filed a Joint Plan of Reorganization under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Court”). | a19-2907_28k.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 7.01 Regulation FD Disclosure | 7.01 On January 7, 2019, Robert Radie, President and Chief Executive Officer of the Company, will be using the presentation furnished as Exhibit 99.1 hereto at the J.P. Morgan Healthcare Conference. | a19-2005_18k.htm |